News | March 14, 2023
Pfizer acquires Seagen for US$ 43 billion to battle cancer
Proposed combination enhances Pfizer’s position as a leading company in oncology
Proposed combination enhances Pfizer’s position as a leading company in oncology
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
The business serves the healthcare and laboratory sectors on the west coast of the United States.
This acquisition will boost Neogen's portfolio by offering organolithium derivatives to existing pharma industry
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
A total of 889 M&A deals were announced in the medical devices sector in 2022 worth $93 billion
Agasta Software is engaged in research, development and commercialization of medical devices
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
Subscribe To Our Newsletter & Stay Updated
